Your Eyes Are Dry. Your Genes May Be Controlling It.

Your vitamin D receptor acts as a master switch for immune tolerance in your tear glands and ocular surface. When VDR is functioning normally, it dampens autoimmune responses against your own lacrimal tissue and helps maintain a healthy epithelial barrier on your cornea and conjunctiva.

Variants in VDR (particularly the f allele and bb genotype) reduce the effectiveness of vitamin D signaling. This means even if your vitamin D levels are normal or high on blood tests, your cells aren’t responding properly to the vitamin D that’s present. People with VDR variants experience more aggressive immune infiltration into tear glands and a compromised corneal epithelial barrier. Your immune system treats your tear-producing tissue more like an invader than your own cells.

You likely notice dry eyes that worsen in winter (when vitamin D is lower) or flare after sun avoidance. Your eyes may feel sand-papery even right after using drops. The problem is that your corneal surface isn’t healing properly between blinks because your epithelial barrier repair is compromised.

MTHFR catalyzes one of the most important biochemical steps in your body: converting dietary folate into the active form your cells use for methylation, DNA repair, and antioxidant production. Your tear glands, corneal epithelium, and blood vessels supplying your eyes all depend on this step working efficiently.

The C677T variant, carried by roughly 40% of people with European ancestry, reduces MTHFR enzyme activity by 40-70%. This cascades into two critical problems for dry eye: first, impaired methylation means your tear glands can’t produce adequate mucin and aqueous layers of the tear film. Second, impaired homocysteine metabolism leads to elevated homocysteine, which damages the delicate blood vessels supplying your lacrimal glands and ocular surface. You end up with both reduced tear production and compromised vascular delivery to the tissue that makes tears.

With MTHFR variants, your dry eyes often come with other signs of methylation dysfunction: fatigue, brain fog, or mood sensitivity. Your eyes may improve briefly with standard drops but never fully stabilize. You may have noticed your eyes got worse after starting high-dose folic acid supplements (the wrong form for your genetics).

TNF-alpha is your immune system’s primary alarm bell. In small amounts it protects you. In excess, it becomes a wrecking ball. Your TNF gene controls how much of this cytokine your immune cells produce in response to stress, infection, or perceived threats.

The -308G>A variant in the TNF promoter, carried by roughly 30% of people with European ancestry, increases TNF-alpha production. This means your immune system mounts a more aggressive inflammatory response to any trigger. For your eyes, this is devastating: elevated TNF-alpha directly drives lymphocytic infiltration into your lacrimal glands and accelerates autoimmune attack on your tear-producing tissue. It also increases tear film evaporation by damaging your lipid layer (produced by meibomian glands, which are also TNF-sensitive).

If you have this variant, your dry eyes likely flare after stress, poor sleep, or dietary inflammatory triggers (processed foods, excess omega-6 oils, sugar). Your eyes feel worse, not better, with standard moisturizing drops alone because the underlying inflammation keeps driving tissue damage faster than drops can compensate.

IL-6 is inflammation’s megaphone. Once TNF-alpha or other triggers activate your immune system, IL-6 amplifies the signal and prolongs the inflammatory response. Your IL6 gene controls your baseline IL-6 production and how aggressively your cells respond to inflammatory signals.

The -174G>C variant in the IL6 promoter, present in roughly 40% of the population, increases IL-6 production. This means your tear glands and ocular surface are bathed in higher levels of this inflammatory cytokine, driving persistent immune infiltration and epithelial damage. Unlike TNF which is primarily upstream, IL-6 is the amplifier that keeps inflammation going even after the initial trigger is gone. People with this variant often describe dry eyes that flare and then never fully resolve; the inflammation rebounds quickly.

You may notice your dry eye is worse on days with systemic inflammation markers: after a poor night of sleep, during allergy season, or when you have a cold. Your eyes feel gritty and irritated even with aggressive eye drop use because you’re fighting an inflammatory fire that drops can’t extinguish.

SOD2 is your mitochondria’s primary defense against oxidative stress. Your tear glands and retinal tissue are extremely high-energy tissues, constantly producing reactive oxygen species (ROS) as a byproduct of ATP generation. SOD2 neutralizes these ROS before they damage cellular machinery. Without adequate SOD2 function, oxidative stress accumulates and your cells can’t maintain normal function.

The Val16Ala variant (rs4880), present in roughly 40% of the population as the homozygous Ala/Ala genotype, reduces SOD2 mitochondrial targeting efficiency. This means oxidative stress accumulates in your tear-producing cells and corneal epithelium faster than normal. Oxidative stress directly damages the delicate lipid membranes in your lacrimal gland cells and accelerates epithelial cell death on your cornea. Your tear glands essentially age faster, and your corneal cells can’t regenerate as quickly as they’re being damaged.

With SOD2 variants, your dry eye may have an oxidative signature: it worsens with UV exposure, screen time (which increases metabolic demand in photoreceptors), or environmental irritants. You may also notice symptoms suggesting systemic oxidative stress: fatigue after exercise, slow recovery from infections, or premature skin aging.

COMT breaks down dopamine, adrenaline, and noradrenaline. Your COMT activity directly influences your autonomic nervous system balance and your stress resilience. COMT also controls dopamine availability in your tear-producing tissue, where dopamine helps regulate tear secretion and lacrimal gland function.

The Val158Met variant, present in roughly 25% as the homozygous slow (Met/Met) genotype, slows COMT enzyme activity. This means dopamine lingers longer in your neural tissue (which sounds good) but also means your stress response stays activated longer (which is not). For your eyes, the effect is paradoxical: slow COMT can improve dopamine-driven tear secretion initially, but the elevated sympathetic tone (fight-or-flight dominance) chronically suppresses parasympathetic tear production. You end up with reduced tear flow because your autonomic nervous system is stuck in stress mode.

If you have this variant, your dry eyes likely worsen with stress, caffeine, or high-intensity exercise. You may notice your eyes feel drier in the afternoon (after accumulated daily stress) or when you’re anxious. Your tear production may be adequate at rest but plummets during demanding cognitive work or emotional stress.